South San Francisco, United States
Spruce Biosciences, established in 2016, is a United States-based clinical stage biopharmaceutical company. Their slogan, "Advancing Treatments for Congenital Adrenal Hyperplasia and Other Rare Endocrine Disorders," succinctly outlines their focus on developing pioneering therapies for rare endocrine diseases.
Specializing in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries, Spruce Biosciences has captured attention for its targeted approach to addressing unmet medical needs.
The company's recent financial milestone was a $53.60M post-IPO equity investment in February 2023, highlighting strong investor confidence. Key stakeholders include prestigious names such as Novo Holdings, 5AM Ventures, Abingworth, HealthCap, RiverVest, Rock Springs Capital, and Armistice Capital. This substantial backing underscores their strategic potential in the niche yet impactful area of endocrine disorder therapeutics.
Soleno Therapeutics, Inc.